Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
Clinical trial NCT02743819 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02743819
- Sponsor
- University of Chicago
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-28
- Primary completion
- 2022-06-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.